Deoxygenation of erythrocytes from sickle cell anemia (SCA) patients alters membrane phospholipid distribution with increased exposure of phosphatidylethanolamine (PE) and phosphatidylserine (PS) on the outer leaflet. This study investigated whether altered membrane phospholipid exposure on sickle erythrocytes results in complement activation. In vitro deoxygenation of sickle but not normal erythrocytes resulted in complement activation measured by C3 binding. Additional evidence indicated that this activation was the result of the alterations in membrane phospholipids. First, complement was activated by normal erythrocytes after incubation with sodium tetrathionate, which produces similar phospholipid changes. Second, antibody was not required for complement activation by sickle or tetrathionate-treated erythrocytes. Third, the membrane regulatory proteins, decay-accelerating factor (CD55) and the C3b/C4b receptor (CD35), were normal on sickle and tetrathionate-treated erythrocytes. Finally, insertion of PE or PS into normal erythrocytes induced alternative pathway activation. SCA patients in crisis exhibited increased plasma factor Bb levels compared with baseline, and erythrocytes isolated from hospitalized SCA patients had increased levels of bound C3, indicating that alternative pathway activation occurs in vivo. Activation of complement may be a contributing factor in sickle crisis episodes, shortening the life span of erythrocytes, and decreasing host defense against infections. (J. Clin. Invest. 1993. 92:1326-1335
Introduction
Sickle cell anemia (SCA)' is a genetic disease resulting from a single amino acid change in the ,3-globin subunit of hemoglobin (1) . This abnormal hemoglobin is termed hemoglobin S (Hb S), and homozygous individuals (Hb SS) develop a chronic hemolytic anemia, chronic and progressive tissue and organ damage, and acute painful vasoocclusive crises. Erythrocytes from SCA patients when exposed to low oxygen pressure become deformed into a sickle shape as a result ofpolymerization of Hb S within the cell. Sickle erythrocytes have a shorter life span than normal erythrocytes and are less elastic, more easily trapped in capillaries, and more prone to physiological insults ( 1, 2) . Sickle erythrocytes also have altered membrane phospholipid distribution after deoxygenation (3) (4) (5) .
Phospholipids on normal human erythrocytes are asymmetrically distributed across the bilayers of the cell membrane (5, 6) . Phosphatidylcholine (PC), sphingomyelin, and < 10% of the total phosphatidylethanolamine (PE) are located in the external leaflet. Most of the PE and all of the phosphatidylserine (PS) are located on the inner leaflet of the membrane bilayer. Deoxygenation of Hb SS erythrocytes results in increased exposure of PE and PS on the outer leaflet (3) (4) (5) . The abnormal exposure of PS on sickle erythrocytes has been related to increased adherence to endothelial cells (2) , procoagulant activity (7) , and adherence to mononuclear phagocytic cells (8, 9) .
Patients with SCA are susceptible to recurrent bacterial infections, particularly with Streptococcus pneumoniae (10) . The higher propensity for bacterial infections has been attributed to decreased splenic function (11) . Abnormal opsonic activity (12) (13) (14) and evidence ofalternative complement pathway activation (15) (16) (17) (18) have been observed in serum from patients with SCA, suggesting that decreased serum complement may also contribute to the higher risk of bacterial infections. The source of this complement activation has not been determined.
The alternative complement pathway is a primary host defense mechanism, which can be activated by bacterial polysaccharides, virus-infected cells, and other substances in the absence of specific antibodies ( 19, 20) . Upon activation, C3b molecules are deposited covalently on the activator surface leading to opsonization and formation of the lytic membrane attack complex. Liposomes containing PE (21) and/or PS (22) (23) (24) activate the alternative complement pathway in human serum. C3b deposition on normal host cells is inhibited by membrane regulatory proteins, including decay-accelerating factor (DAF, CD55) (25), membrane cofactor protein (MCP, CD46) (25), and the C3b/C4b receptor (CR1, CD35) (26) . DAF, MCP, and CR1 efficiently modulate complement activation by both the classical and alternative pathways by preventing the formation ofC3 and C5 convertases on autologous cells and promoting the breakdown of bound C4b and C3b (27) (28) (29) (30) (31) . Of these, only DAF and CR1 are found on erythrocytes.
The present work has tested the hypothesis that membrane phospholipid changes in deoxygenated sickle erythrocytes lead to complement activation through the alternative pathway. The results indicate that deoxygenated sickle erythrocytes activate the alternative complement pathway in autologous serum and that similar activation can be induced by several other treatments that increase PE and PS exposure on normal erythrocyte membranes. Complement activation occurs despite apparently normal membrane regulatory proteins, DAF and CR 1. Analysis of cleaved complement factor B in plasma samples from SCA patients at baseline and in crisis and of bound C3 fragments on erythrocytes from hospitalized and nonhospitalized patients indicate that alternative pathway activation occurs in vivo during sickle crisis episodes.
Methods
SCA patients and normal donors. Venous blood was collected from individuals with Hb SS disease followed at the Duke University Comprehensive Sickle Cell Center's Adult Clinic at the time of routine visit to the clinic or from hospitalized patients for routine blood cell analysis. Homozygous hemoglobin A (Hb AA) donors were normal volun- (36) , and factor D (37) were purified as described. Functionally purified factor 1 (35) was further purified on an affinity matrix prepared using goat antifactor I (Quidel, San Diego, CA) and CarboLinkO coupling gel (Pierce Chemical Co., Rockford, IL). Human C2 and C4 were purchased from Quidel. Purified C3 was labeled with [ '25I ] sodium iodide (ICN Biochemicals, Inc., Costa Mesa, CA) to a specific activity of -0.1 ,uCi/,ug using Iodo-beads® (Pierce Chemical Co.).
Complement activation by human erythrocytes. Autologous serum containing 2.5 mM MgCl2 and 10 mM EGTA to block the classical pathway and permit activation ofthe alternative pathway was added to an equal volume of erythrocyte suspension at a concentration of 109 cells/ml. Control samples were incubated with autologous serum chelated with 10 mM EDTA to block both complement pathways. Serum and erythrocyte mixtures were incubated for 30 min at 37°C, washed with VBS containing 0.1% gelatin (GVB), and lysedin PBS containing either 0.5% Triton X-100 or 0.5% NP-40. Samples were stored at -70°C before testing C3 deposition.
The purified alternative complement pathway was prepared using C3, MgCl2, and factors B, D, H, I, and P at their physiological concentrations in GVB as previously described (38) . Human erythrocytes at I09 cells/ml in VBS were incubated with an equal volume ofthe purified component mixture for 30 min at 370C. After incubation, erythrocytes were washed, lysed, and frozen before testing C3 deposition. C3 binding assays. A competitive ELISA using horseradish peroxidase-conjugated anti-C3 antibody (Cappel Laboratories, Durham, NC) was used to quantitate C3 deposition on erythrocytes as previously described (21). The amount of C3 bound to erythrocytes was calculated from a standard curve prepared using 0.03-8 jg/ ml purified C3. Values from EDTA controls were subtracted. The assay detects C3d as well as intact C3, C3b, and iC3b. The molecular weight of C3b was used to calculate molecules bound per cell. For experiments to assess the presence of C3 fragments on washed erythrocytes without serum incubation, washed erythrocytes were lysed at a concentration of 6.7 X 108 cells/ml and added to the ELISA. Rabbit erythrocytes prepared in the same way were used to determine a negative control value, which was subtracted from the data.
The same washed erythrocytes were tested for the presence ofC3 by a flow cytometric assay. 1O8 erythrocytes were incubated with polyclonal goat anti-human C3 (Quidel) that had been affinity purified by absorption and elution from C3b bound to activated thiol Sepharose®, washed with GVB, and incubated with FITC-conjugated rabbit antigoat IgG (Sigma Chemical Co., St. Louis, MO). Controls were incubated with second antibody only or with no antibody. Fluorescence was measured on an EPICS CO fluorescence-activated cell sorter (Coulter Corp., Hialeah, FL). Staining observed with the FITC-conjugated secondary antibody was subtracted from staining observed with both antibodies for each sample using Immunoanalysis software (Coulter Corp.). Staining with the second antibody was not significantly greater than autofluorescence.
In vitro deoxygenation/oxygenation oferythrocytes. Human erythrocytes resuspended in VBS were gently bubbled with pure nitrogen (deoxygenated) or oxygen (oxygenated) at room temperature for 5 min. Erythrocyte suspensions were then incubated either sealed (deoxygenated) or not sealed (oxygenated) for 2 h at 37°C. After incubation, cells were washed again and resuspended in VBS to a final concentration of 109 cells/ml before incubation in autologous serum. Tetrathionate treatment oferythrocytes. Human erythrocytes from Hb AA donors were incubated with sodium tetrathionate, a thiol-oxidizing agent, as described (39). 1 ml of packed erythrocytes was resuspended in 9 ml of a buffer solution containing the following (mM): 90 KCl, 45 NaCl, 10 sodium phosphate, and 44 sucrose (pH 8.0). Cell suspensions were incubated at 37°C with different concentrations of sodium tetrathionate for the times indicated in the results. After incubation, cells were washed and resuspended in the same buffer. A fluorescent probe, merocyanine 540 (MC540; Sigma Chemical Co.), was used to measure membrane phospholipid changes on sodium tetrathionatetreated erythrocytes as previously described (40) . Increased binding of MC540 correlates with increased exposure of inner leaflet phospholipids containing unsaturated fatty acyl side chains on the outer leaflet of erythrocyte membranes (40) and has been shown to correlate with measurement of PE and PS exposure on erythrocytes by other methods. Cell suspensions were incubated with MC540 at a final concentration of 4 jg/ml for 4 min at room temperature. After incubation, the binding ofMC540 was measured directly using a spectrofluorophotometer (Shimadzu Scientific Instruments, Inc., Columbia, MD) (excitation X, 570 nm; emission X, 612 nm).
Assayfor total serum alternative complement pathway. Serum was assayed for alternative pathway activity by a hemolytic assay (41). Serum samples serially diluted in VBS containing 2.5 mM MgCl2 and 10 mM EGTA were incubated with rabbit erythrocytes for 30 min at 37°C. VBS containing 10 mM EDTA was added to stop the activation, samples were centrifuged, and absorbance of supernatants was read at 541 nm for hemolysis. The serum dilutions resulting in 50% hemolysis (CHo) were calculated as previously described (41).
DAF and CRI antigen levels. DAF and CR1 expression on human erythrocytes were determined using anti-DAF mAb IIH6 (42) Functional activityofDAF. DAF was purified from human erythrocytes as described (43) . Purified DAF was incorporated into complement-activating liposomes containing dipalmitoyl-phosphatidylethanolamine (DPPE), dipalmitoyl-phosphatidyicholine (DPPC), and cholesterol (molar ratio 4:6:5 ) at a concentration of 1 ,ug ofDAF/MUmol phospholipid as previously described (44). Liposomes were incubated at 370C for 1 h in the presence of 20 mM sodium tetrathionate. After treatment, liposomes were incubated with normal human serum, washed, lysed, and C3 deposition was determined by ELISA. Tetrathionate-treated liposomes were compared with untreated liposomes containing or lacking DAF.
The functional activity of DAF in human erythrocytes was measured by its ability to inhibit the classical pathway C3 convertase, C4b2a (43) . DAF inhibits this convertase by dissociating C2a from C4b (45 ) . Human erythrocytes ( 100 Ml at I09 cells/ml) were incubated sequentially with rabbit anti-human erythrocyte serum (final concentration 1:1600) (Cappel Laboratories), human euglobulin C1 (20 Mig), human C4 (4 Mg), and human euglobulin Cl (20 Mig), with washing between each step, to form huEAC14b. To assess C3 convertase function, 7.5 ng oxidized human C2 (OXYC2) (43, 46) was added to 2.5 X 107 huEAC14b in 50 Ml GVB2+ (GVB containing 0.15 mM CaCI2 and 0.5 mM MgCl2) and incubated for 5 min at 30°C to form the C3 convertase. Then 100 Ml of ['251I]C3 (50 Mug) was added directly to the mixture in 100 ,l GVB containing 10 mM EDTA (to prevent further convertase formation), and the cells were incubated for 30 min at 37°C. After incubation, cells were washed three times and bound ['251I]C3 was determined by counting the pellets using a gamma counter (Minaxi®; Packard Instruments Co. Inc., Downers Grove, IL). As controls, normal erythrocytes were incubated for 30 min on ice with anti-DAF mAbs (IA10, IIH6, and VIIIA7) (42, 43) to inhibit DAF function before incubation with rabbit anti-human erythrocyte antibody, Cl, C4, and C2, and measurement of [125I]C3 binding. Anti-DAF treatment did not affect the amount of C4 bound to the erythrocytes after antibody, C1, and C4 incubations.
Functional activity ofCR1. The function of CR1 was determined by its cofactor activity for factor I-dependent cleavage of bound C3b (47, 48) . 107 sheep erythrocytes with bound [ 251I]C3b deposited by the classical pathway as described (48) were incubated with 2 X 107 human erythrocytes in the presence of 1 Mug ofpurified factor I for 30 min at 37°C. After incubation, supernatants were analyzed by 5-15% gradient SDS-PAGE and autoradiography. CR1 function on erythrocytes from different individuals was compared by the density of the released 27-kD C3c fragment on the autoradiograph.
Insertion ofphospholipids into erythrocytes. Synthetic dipalmitoylphosphatidylserine (DPPS) was purchased from Sigma Chemical Co. Synthetic DPPC and DPPE were purchased from Calbiochem Corp. (La Jolla, CA). Phospholipid mixtures made ofDPPC/NBD-PC, DPPS/NBD-PS, or DPPE/NBD-PE with molar ratio 4:1, 4:1, and 29:1 respectively, were dissolved in pure chloroform and dried under nitrogen. Vesicles were then prepared by sonication of 5 Mg/ml (DPPC/NBD-PC and DPPS/NBD-PS) or 30 Mg/ml (DPPE/NBD-PE) in PBS for 10 min at room temperature with a probe sonicator (Ultrasonic Power; Freeport, IL) as described (8) . Contaminating large multilamellar vesicles were removed from the suspension by centrifugation at 2,000 g for 15 min.
Phospholipid vesicles were incubated with erythrocyte suspensions for 30 min at 37°C (8) . After incubation, erythrocytes were washed and resuspended at I09 cells/ml in VBS before autologous serum incubation. The mean channel fluorescence of treated erythrocytes was measured by flow cytometry using fluorescein settings. Phospholipid incorporation was then calculated from standard curves of mean channel fluorescence versus incorporation for each phospholipid. To construct the standard curves, phospholipid incorporation for a range of vesicle/erythrocyte ratios was determined by fluorimetry of fully dequenched unincorporated vesicles compared with pure phospholipid standards (excitation X, 470 nm; emission A, 525 nm) and plotted against the mean channel fluorescence readings of the erythrocytes. Insertion of labeled lipid into erythrocyte membranes was confirmed by visual observation of bright uniform rings of membrane fluorescence in treated cells. To determine whether adherent vesicles were present in the treated erythrocyte preparations, fluorescence (excitation X, 470 nm; emission A, 525 nm) oftreated erythrocytes was determined in the presence and absence of 2% Triton X-100. Because ofthe self-quenching properties of the labeled phospholipids, the phospholipid vesicles show about a 10-fold increase in fluorescence after lysis (8) . Lipid that has inserted into the erythrocyte membrane by contrast is dequenched by dilution with membrane lipids and its fluorescence is not increased by detergent solubilization. The erythrocytes used for complement activation studies did not show increased fluorescence after lysis, indicating minimal contamination with intact vesicles.
Plasma Bb. Plasma Bb concentration was measured using a commercial ELISA from Quidel. Paired plasma samples were obtained from three SCA patients at baseline and during acute sickle crisis episodes. Patients were considered to be at baseline ifthey had no pain or fever at the time of presentation and returned a postcard 48 h later stating that they had not experienced pain or fever in the 48 h after their samples were drawn. Patients were considered to have pain crisis when they presented to the emergency department or clinic with pain that was consistent with their usual sickle cell pain crisis; no other cause was found for the pain; and there was no resolution of pain after 8 h of treatment with parenteral narcotics. Five additional plasma samples from three other SCA patients with chronic pain were also analyzed.
Statistical analysis. Comparisons between means were made using the t test with P < 0.05 considered to be significantly different.
Results
Activation ofthe alternative complementpathway by deoxygenated erythrocytesfrom SCA patients. Deoxygenated or oxygenated erythrocytes obtained from SCA patients during routine clinic visits and healthy controls were incubated with MgEGTA-treated autologous serum and alternative pathway activation determined by C3 deposition (Fig. 1) bution in normal erythrocytes would induce complement activation, Hb AA erythrocytes were treated with 5 mM sodium tetrathionate for 0-3 h or with 2.5-20 mM sodium tetrathionate for 1 h at 37°C. Membrane phospholipid changes were monitored by fluorimetry using MC540, which binds to inner leaflet phospholipids. Increased binding of MC540 has been shown to correlate with exposure of PE and PS (40) . MC540 binding increased with incubation time (Fig. 2 ) and sodium tetrathionate concentration (Fig. 3) . A corresponding increase in complement activation by tetrathionate-treated erythrocytes after incubation in MgEGTA-treated autologous serum was observed (Figs. 2 and 3) . Erythrocytes from the same donors incubated in buffer showed little increase in MC540 binding or C3 deposition.
Activation ofthe purified alternative pathway by tetrathionate-treated and sickle erythrocytes. Naturally occurring antibody that binds to clustered band 3 on senescent and diamidetreated erythrocytes has been reported to enhance complement activation (52) . To determine whether antibody was required for complement activation by tetrathionate-treated erythrocytes, erythrocytes from Hb AA normal donors were treated with 5 mM tetrathionate for 3 h or 20 mM tetrathionate for 1 h and C3 deposition measured after incubation with the six purified components ofthe alternative pathway. As shown in Fig. 4 a, tetrathionate-treated erythrocytes activated complement in this purified mixture in the absence ofantibody. Deoxygenated sickle erythrocytes also activated complement after incubation with purified alternative pathway components (Fig. 4 b) . Tetrathionate-treated erythrocytes activated complement in serum that had been absorbed with tetrathionate-treated erythrocytes to remove antibody to band 3 or other erythrocyte molecules (data not shown). Antigenic andfunctional levels ofDAF and CRI in sickle and tetrathionate-treated erythrocytes. To determine whether decreased levels or activities of regulatory proteins contributed to the complement activation observed after deoxygenation or tetrathionate treatment, the antigenic and functional levels of DAF and CR1 were studied. As shown in Table I The cofactor function of erythrocyte membrane CR1 was tested by incubating sheep erythrocytes bearing [ 25I]C3b with human erythrocytes and purified factor I and measuring the release of the cleavage product C3c. CR1 cofactor activity on deoxygenated sickle erythrocytes from six patients and tetrathionate-treated normal erythrocytes was not different from the activity of erythrocytes from normal donors (Fig. 6 and Table  III ). C3c release required both factor I and human erythrocytes (data not shown).
Alternative pathway activation after insertion ofPE and PS into normal erythrocytes. As a method of altering membrane phospholipid composition without disrupting the cytoskeleton, normal erythrocytes were incubated with synthetic phospholipid vesicles to increase PE, PS, or PC concentration in the membrane. Insertion was measured with fluorescent phospholipids. As shown in Fig. 7 , Hb AA erythrocytes activated the alternative pathway in autologous serum after insertion of low concentrations of PE or higher concentrations of PS, but not (Fig. 8) .
Paired plasma samples isolated from three SCA patients demonstrated a twofold higher Bb fragment concentration in crisis compared with baseline (P = 0.037). Bb levels in samples from SCA patients at baseline were not significantly higher than normal controls (P > 0.05). Five SCA patients characterized clinically as suffering from chronic pain also showed increased plasma Bb concentrations compared with normal controls (P = 0.001 ).
Erythrocytes with bound fragments of C3 (C3d and C3dg) have been reported in several hemolytic anemias and systemic autoimmune diseases (53) . Although initial experiments indicated that the amount of C3 bound to cells from healthy SCA patients was very low, we examined erythrocytes from a larger number of hospitalized and nonhospitalized SCA patients for bound C3 using the competitive C3 ELISA (Fig. 9 ) and flow cytometry with anti-C3 antibody. The results of both assays showed significantly increased C3 on erythrocytes from patients compared with controls. By ELISA, control erythrocytes had an average of 74±23 C3 molecules per cell, erythrocytes from outpatients had 369±122 C3 molecules per cell, and erythrocytes from hospitalized patients had 855±147 C3 molecules per cell. These values were significantly higher for hospitalized patients compared with controls (P = 0.0001 ), hospitalized patients compared with outpatients (P = 0.028), and outpatients compared with controls (P = 0.021 ). By flow cytometry erythrocytes from hospitalized patients and outpatients had a significantly higher percentage of cells stained by anti-C3 antibody and significantly higher mean fluorescence of the positive cells compared with erythrocytes from normal donors (data not shown). These results and the Bb data (Fig.  8) indicate that alternative pathway activation in SCA patients correlates with periods of crisis and that SCA erythrocytes are involved in this activation.
Discussion
This study demonstrates activation of the alternative complement pathway in autologous serum by deoxygenated sickle erythrocytes. Several lines of evidence indicate that this complement activation is the result of the increased appearance of PE and PS in the outer membrane leaflet of these cells.
Alternative pathway activation is initiated by the binding of C3b to surfaces ( 19, 20) . The bound C3b then assembles the alternative pathway C3 convertase, C3bBb, by the binding of factor B and its cleavage by factor D. The C3 convertase cleaves additional C3 creating a positive amplification loop for the deposition ofC3b on the activating surface. Membrane-bound C3b molecules facilitate phagocytosis and can further activate CS through C9 to form lytic membrane attack complexes. The alternative pathway is a tightly regulated system in which inter- sheep erythrocytes incubated with buffer alone, factor I alone, factor I and 5 ug H (to produce iC3b), and factor I and sheep E (lacking CR1).
Results of this and additional experiments are summarized in Table III. actions between the activating surface, C3b, and regulatory proteins determine whether amplification will take place. Previous results from our laboratory (21) and others (22, 23, 54) have shown that liposomes containing PE or PE and PS or inside-out vesicles prepared from erythrocytes activate the alternative complement pathway. Thus, it seemed possible that Cts an increase of 9-18% erythrocytes. However, as noted, the concentrations of PE in-.lar to the concentration serted were also much lower than the amount ofPE exposed by
Iytes In contrast, PC inthe treatments, and possible combined effects of PE and PS tivation at the same conwere not examined. On the basis of these studies and previous studies using liposomes (21) (22) (23) (24) , complement activation is apparently more sensitive to PE exposure than to PS exposure. In contrast, PS has been implicated in activation of the coagulation pathway and in binding of erythrocytes to monocytes (2, (7) (8) (9) .
Complement activation on autologous cells is normally blocked by membrane regulatory proteins. On erythrocytes there are two membrane proteins that regulate C3 convertases, DAF (43) and CR1 (26) . DAF is a phosphatidylinositol-anchored membrane protein, which promotes the dissociation of C3 convertases, preventing further complement activation (57) . CR1 is a receptor for complement-fixing immune complexes (26 the function ofDAF and CR1 were detected in sickle or tetrathionate-treated erythrocytes. This is consistent with the low levels of C3 found on erythrocytes isolated from healthy SCA patients before deoxygenation and serum incubation. Increased bound C3 in the form of C3d and C3dg has been reported in conditions of ongoing complement activation associated with reduced CR1 or DAF levels (53) . This also indicates that in vitro complement activation by sickle and tetrathionate-treated erythrocytes resulted from the increased appearance ofactivators rather than decreased function ofregulatory proteins. The degree to which complement activation may have been limited by the regulatory proteins was not determined in these experiments. Studies in liposomes in which inserted PE leads to complement activation have demonstrated that this activation is sensitive to inhibition by DAF (44).
Previous studies (15) (16) (17) (18) have found evidence of ongoing complement activation in SCA patients. For the most part, no cause of the complement activation was hypothesized, although one study ( 15) reported a correlation between C3d levels and hemoglobin and suggested that intravascular hemolysis leads to complement activation in these patients. We have demonstrated here an increase in factor Bb (53) . The levels ofC3 found on erythrocytes from hospitalized SCA patients (855±147 molecules/cell), although higher than controls, are much lower than the mean of 8,673+7,151 molecules/cell found on erythrocytes from patients with cold agglutinin disease, an autoantibody-mediated hemolytic anemia.
Complement activation may also contribute to the decreased resistance to bacterial infections in SCA patients. Although we did not find decreased complement in serum from SCA patients studied at baseline, we did find evidence of activation during crisis. In addition, phagocytosis ofsickle erythrocytes by macrophages after complement activation (59) or by direct recognition of exposed PS (8) may overload the phagocytic clearance system, preventing its normal function in the removal of invading microorganisms.
Erythrocyte membrane phospholipid redistribution is not unique to sickle erythrocytes. Increased exposure of PE and PS has been reported in senescent or aged erythrocytes (60), erythrocytes from chronic myeloid leukemia patients (61 ) , and malaria-infected erythrocytes (62) . For some of these conditions, there is evidence for complement activation as well (63, 64) . Increased PS has been shown to enhance senescent erythrocyte adherence to phagocytes and endothelial cells (2, 8, 9) . We have found that human red blood cells aged in vitro can activate the alternative complement pathway resulting in increased C3 deposition (Wang, R., unpublished results). Malaria-infected erythrocytes have increased exposure of PE and PS (62) , increased surface C3 binding, and increased phagocytosis by macrophages (59) .
In summary, we have presented evidence that altered membrane phospholipid distribution on human erythrocytes is sufficient to initiate complement activation perhaps contributing to opsonization and clearance of abnormal erythrocytes in SCA and other conditions.
